Brain, Cancer
Conditions
Keywords
ketogenic, diet, gliomas, metastases
Brief summary
The survival interval of patients with gliomas ranges between 12 to 15 months. Recent findings revealed that dietary interventions to reduce glucose and glycolytic pathways could have a therapeutic effect. Ketosis can be an effective therapy to extend the survival of patients with gliomas.
Detailed description
Gliomas are invasive and aggressive tumors, which derive from glial or stem cells, and after neoplastic transformation, acquire glial cell characteristics. Treatment of high-grade gliomas includes measures to relieve symptoms and eliminate or control the tumor. Surgery, radiation, and chemotherapy are the most common options. Recent findings revealed that dietary interventions to reduce glucose and glycolytic pathways could have a therapeutic effect. CKD is a restrictive therapeutic diet consisting of a 4:1 ratio of fat-to-CHO and protein. Fat provides up to 90% of the caloric intake, while overall CHO intake is less than 50 g/day. CKD reducing blood glucose levels and increasing ketone body levels stimulates biochemical changes to achieve systemic ketosis. Though, evidence for CKD in clinical practice is still limited. This study focuses on the classic ketogenic diet (CKD), adjusted for each patient's energy needs by dieticians to achieve ketosis. The primary outcome is to assess the efficacy of CKD to extend the survival of patients with high-grade gliomas and brain metastases. Historical controls will be used to compare the outcome measurements.
Interventions
OTHERCKD
Patients/families will meet with the study dietician to discuss the CKD, ask questions, and plan clinic visits. Training will take place about diet, meal planning, and ketones/glucose monitoring. The dietitian will follow the patient throughout treatment. Patients will measure their urine ketosis with urine test strips and capillary ketones with blood ketone meters daily, and they will complete records from the start till the end of the study. Finally, they will meet with the dietitian at follow-up visits and on an as-needed basis.
Sponsors
Attikon Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Patients will adhere to a classic ketogenic diet for a period of 3 months with a possible extension depending on their compliance on the diet.
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Age 18-80 * Karnofsky Performance Score of 50 or more. * Newly diagnosed, histologically confirmed glioblastoma grade 4, or secondary metastases or progression after surgical resection, radiation and chemotherapy. * Normal function of liver and kidneys * Ability to sign informed consent form
Exclusion criteria
* Diabetes mellitus * Life expectancy \>3 months * Inability to adhere to diet * Inability to give informed consent form * Cholecystectomy last 1 year (before the study entry) * Diagnosis of genetic disorder of fat metabolism
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival | Participants will be followed from date of randomization until the date of death from any cause, assessed up to 36 months. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in brain tumor size | 2 years, Baseline, 3, 6, 12, and 24 months | MRI (Magnetic Resonance Imaging) will be used to measure changes in tumor size (cm\^2) |
| Time to progression | 2 years | — |
| Assessment of Quality of life using FACT-BR (version 4) survey | Baseline, 3, 6, 12 months | 50-item FACT-Br (Functional Assessment of Cancer Therapy - Brain) is a self-report and interview when applicable questionnaire used to assess quality of life, which includes domains such as Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, Brain Cancer Subscale. Each of them is rated based on the Likert scale from 1 to 5. |
| Functional impairment will be assessed with the Karnofsky Performance Scale | Baseline, 3, 6, 12 months | The scoring is assigned by a health professional based on the hierarchical scale: 100=normal, no evidence of disease, while 10=death. Intermediate or decimal scores can be assigned. |
Countries
Greece
Contacts
Primary ContactArezina N. Kasti, RD
Backup ContactEvangelos K. Papadopoulos, MD
Outcome results
None listed